James Kihara - ACADIA Pharmaceuticals Chief VP
ACAD Stock | USD 14.79 0.06 0.40% |
Insider
James Kihara is Chief VP of ACADIA Pharmaceuticals
Age | 43 |
Address | 12830 El Camino Real, San Diego, CA, United States, 92130 |
Phone | (858) 558-2871 |
Web | https://www.acadia.com |
Latest Insider Transactions
James Kihara Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Kihara against ACADIA Pharmaceuticals stock is an integral part of due diligence when investing in ACADIA Pharmaceuticals. James Kihara insider activity provides valuable insight into whether ACADIA Pharmaceuticals is net buyers or sellers over its current business cycle. Note, ACADIA Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell ACADIA Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Kihara over a month ago Disposition of 1489 shares by James Kihara of ACADIA Pharmaceuticals subject to Rule 16b-3 |
ACADIA Pharmaceuticals Management Efficiency
As of May 18, 2024, Return On Tangible Assets is expected to decline to -0.09. In addition to that, Return On Capital Employed is expected to decline to -0.16. At present, ACADIA Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 41 M, whereas Non Currrent Assets Other are forecasted to decline to about 2.6 M. ACADIA Pharmaceuticals' management efficiency ratios could be used to measure how well ACADIA Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Todd MD | Hepion Pharmaceuticals | 55 | |
William Ciambrone | Sarepta Therapeutics | 60 | |
Steven MD | Cabaletta Bio | 63 | |
Sharen Pyatetskaya | Hepion Pharmaceuticals | ||
Rebecca MD | Madrigal Pharmaceuticals | 72 | |
Senthil Sundaram | Terns Pharmaceuticals | 46 | |
Tracey Esq | Blueprint Medicines Corp | 56 | |
Louise RodinoKlapac | Sarepta Therapeutics | 46 | |
MS MBA | Krystal Biotech | 59 | |
FACS FACS | PTC Therapeutics | 50 | |
Jenna Cohen | Blueprint Medicines Corp | N/A | |
Alex Kane | PTC Therapeutics | N/A | |
Marianne Mancini | Viking Therapeutics | 59 | |
William JD | Akero Therapeutics | 50 | |
Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
Robert Waltermire | Madrigal Pharmaceuticals | 60 | |
Gloria Lin | Krystal Biotech | N/A | |
FACR MD | Cabaletta Bio | 59 | |
Thomas Schaible | Fortress Biotech | N/A | |
Rachel MBA | Athira PharmaInc | 51 | |
Dr MBA | Blueprint Medicines Corp | 53 |
Management Performance
Return On Equity | -0.0041 | ||||
Return On Asset | -0.0038 |
ACADIA Pharmaceuticals Leadership Team
Elected by the shareholders, the ACADIA Pharmaceuticals' board of directors comprises two types of representatives: ACADIA Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ACADIA. The board's role is to monitor ACADIA Pharmaceuticals' management team and ensure that shareholders' interests are well served. ACADIA Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ACADIA Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Parag PharmD, Senior Franchise | ||
Elizabeth Thompson, Executive Development | ||
Bob Mischler, Senior Strategy | ||
Albert Kildani, Senior Communications | ||
Douglas MD, Executive Development | ||
Stephen JD, CEO President | ||
James Kihara, Chief VP | ||
Jennifer JD, Chief VP | ||
Kimberly Manhard, Senior Execution | ||
Rob Ackles, Senior Officer | ||
Julie Fisher, Senior Strategy | ||
MSPH MD, President | ||
Holly Valdiviez, Senior Sales | ||
Brendan Teehan, COO VP | ||
Erika Zavod, Planning, Strategy | ||
Austin Kim, Executive Vice President General Counsel, Secretary | ||
Sanjeev MD, Senior Development | ||
Mark Schneyer, Executive CFO | ||
Kevin Oliver, Senior Officer | ||
Stephanie Kim, Senior Affairs | ||
Mark Johnson, Vice President Investor Relations | ||
Benir Ruano, Senior Operations | ||
MPH MD, Global SVP |
ACADIA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ACADIA Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.0041 | ||||
Return On Asset | -0.0038 | ||||
Profit Margin | (0) % | ||||
Operating Margin | 0.07 % | ||||
Current Valuation | 2.03 B | ||||
Shares Outstanding | 165.22 M | ||||
Shares Owned By Insiders | 0.48 % | ||||
Shares Owned By Institutions | 99.52 % | ||||
Number Of Shares Shorted | 12.03 M | ||||
Price To Earning | (13.77) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.Note that the ACADIA Pharmaceuticals information on this page should be used as a complementary analysis to other ACADIA Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for ACADIA Stock analysis
When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is ACADIA Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 4.949 | Quarterly Revenue Growth 0.738 | Return On Assets (0) | Return On Equity (0) |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.